UN Panel To Hear Stakeholder Ideas On IP, Innovation And Access
This article was originally published in Scrip
Later this month, the UN high-level panel on access to medicines will hold public hearings to discuss the ideas it has received from stakeholders on how best to ensure access to affordable and high-quality drug treatment while continuing to encourage innovation and the development of new medicines, vaccines and diagnostics.
You may also be interested in...
Heavy-weight United Nations panel makes tough recommendations favoring compulsory licensing – an issue that has riled Big Pharma but has at least one industry proponent, Cipla's chair Yusuf Hamied, who talked to the Pink Sheet about the "excesses" of intellectual property rights.
The head of the European Medicines Agency says a group of international regulators got together to ensure “global alignment” on the approach to be taken on COVID-19 vaccination.
Dissent In Parliament As Commission Claims EU Pharma Revision Will Improve Competitiveness and Access
Proposals on regulatory data protection and transferable exclusivity vouchers to encourage antimicrobial R&D have received mixed reactions from the parliament’s rapporteurs for the draft legislation.